Study: Remdesivir benefits some COVID-19 patients
Excerpt from the article:
“A study published late last week in the New England Journal of Medicine found that hospitalized COVID-19 patients who received Gilead Sciences’ antiviral drug remdesivir recovered a median of 4 days earlier than those who received a placebo.
Preliminary findings from the double-blind Adaptive COVID-19 Treatment Trial (ACTT-1), sponsored by the US National Institute of Allergy and Infectious Diseases (NIAID), showed that the 538 patients randomly assigned to receive remdesivir had a median recovery time of 11 days (95% confidence interval [CI], 9 to 12), compared with 15 days (95% CI, 13 to 19) in the 521 patients who received a placebo (rate ratio for recovery, 1.32; 95% CI, 1.12 to 1.55; P < 0.001).”
Click the button below to read the article:
Discover What Sets TrialStat Apart From Ordinary EDC Platforms
Click the image or button below to explore our eClinical Suite Platform and discover what sets TrialStat apart from competing EDC platforms.
Request Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?